Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report.
Sign Up to like & getrecommendations! Published in 2020 at "Translational lung cancer research"
DOI: 10.21037/tlcr.2020.01.10
Abstract: The efficacy and safety of osimertinib have been demonstrated in several clinical trials; however, acquired resistance is an inevitable problem associated with most targeted drugs. Based on previous findings, the mechanism of osimertinib resistance is… read more here.
Keywords: driver gene; resistance; gene loss; mediated driver ... See more keywords